Study finds colorectal cancer mortality dropping slower in African Americans

December 22, 2011

A new study finds that while colorectal cancer mortality rates dropped in the most recent two decades for every stage in both African Americans and whites, the decreases were smaller for African Americans, particularly for distant stage disease. The authors say concerted efforts to prevent or detect colorectal cancer at earlier stages in blacks could improve worsening black-white disparities.

Before 1980, colorectal for African Americans were lower than those for whites. Since then, however, the pattern of CRC mortality rates has reversed and diverged, so that in 2007, the rate for African Americans was 44 percent higher than for whites. This worsening disparity in mortality rates coincided with the introduction and of screening and improved treatment for colorectal cancer.

Studies show dissemination of screening and improved treatment for colorectal cancer among African Americans has lagged behind whites. However, the extent to which black-white disparities in mortality rates vary by stage at diagnosis is unknown. To find out, American Cancer Society researchers led by Anthony S. Robbins, M.D., Ph.D., examined disparities in stage-specific colorectal cancer mortality rates using the Incidence-Based Mortality database of the National Cancer Institute's Surveillance, , and End Results (SEER) Program.

They found for localized stage, mortality rates decreased 30.3 percent in whites versus 13.2 percent in African Americans. For regional stage disease, those declines were 48.5 percent versus 34.0 percent, respectively. For distant stage, the decreases were 32.6 percent versus just 4.6 percent.

The data indicates that black-white disparities in colorectal cancer mortality increased for each stage of the disease, and that the overall disparity in overall mortality was largely driven by trends for late stage disease. "The widening racial disparity for distant stage has a disproportionate impact on overall CRC mortality because distant stage accounts for approximately 60% of the overall black-white mortality disparity," write the authors.

As to why, the authors cite differences in early detection and differences in treatment. African Americans have historically been less likely than whites to be screened for colorectal cancer. In addition, who are screened often lack timely follow-up. Meanwhile, studies show the dissemination of improvements in treatment has been uneven. Despite its known survival benefit, adjuvant chemotherapy treatment rates among African American patients with colorectal cancer are disproportionately low relative to whites.

Related Stories

Recommended for you

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.